GRAFT POLYMER UK LS -001 (J4I) - Net Assets
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has net assets worth €6.19 Million EUR (≈ $7.24 Million USD) as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.58 Million ≈ $8.87 Million USD) and total liabilities (€1.39 Million ≈ $1.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See J4I net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.19 Million |
| % of Total Assets | 81.62% |
| Annual Growth Rate | 66.17% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 193.91 |
GRAFT POLYMER UK LS -001 - Net Assets Trend (2022–2026)
This chart illustrates how GRAFT POLYMER UK LS -001's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see J4I stock market capitalisation.
Annual Net Assets for GRAFT POLYMER UK LS -001 (2022–2026)
The table below shows the annual net assets of GRAFT POLYMER UK LS -001 from 2022 to 2026. Also explore GRAFT POLYMER UK LS -001 (J4I) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-05-31 | €6.19 Million ≈ $7.24 Million |
+100.75% |
| 2025-05-31 | €3.08 Million ≈ $3.61 Million |
+52.22% |
| 2024-05-31 | €2.03 Million ≈ $2.37 Million |
-55.51% |
| 2023-05-31 | €4.55 Million ≈ $5.32 Million |
+460.84% |
| 2022-05-31 | €812.00K ≈ $949.31K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GRAFT POLYMER UK LS -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1315500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2026)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €22.49 Million | 363.20% |
| Total Equity | €6.19 Million | 100.00% |
GRAFT POLYMER UK LS -001 Competitors by Market Cap
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ARB IOT Group Limited Ordinary Shares
NASDAQ:ARBB
|
$7.91 Million |
|
Evergold Corp
V:EVER
|
$7.91 Million |
|
Canterbury Resources Ltd
AU:CBY
|
$7.92 Million |
|
Humax Holdings Co. Ltd
KQ:028080
|
$7.92 Million |
|
Way 2 Vat Ltd
AU:W2V
|
$7.90 Million |
|
Lite Access Technologies Inc
V:LTE
|
$7.89 Million |
|
Dovre Group Plc
HE:DOV1V
|
$7.89 Million |
|
Banaras Beads Limited
NSE:BANARBEADS
|
$7.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GRAFT POLYMER UK LS -001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 3,084,000 to 6,191,000, a change of 3,107,000 (100.7%).
- Net loss of 5,740,000 reduced equity.
- New share issuances of 4,270,000 increased equity.
- Other factors increased equity by 4,577,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.74 Million | -92.72% |
| Share Issuances | €4.27 Million | +68.97% |
| Other Changes | €4.58 Million | +73.93% |
| Total Change | €- | 100.75% |
Book Value vs Market Value Analysis
This analysis compares GRAFT POLYMER UK LS -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.13x to 1.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-05-31 | €0.01 | €0.00 | x |
| 2023-05-31 | €0.04 | €0.00 | x |
| 2024-05-31 | €0.02 | €0.00 | x |
| 2025-05-31 | €0.00 | €0.00 | x |
| 2026-05-31 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GRAFT POLYMER UK LS -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-92.72%) is below the historical average (-89.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -59.40% | -499.08% | 0.11x | 1.08x | €-3.16 Million |
| 2024 | -154.00% | -531.52% | 0.24x | 1.20x | €-3.32 Million |
| 2025 | -51.56% | 0.00% | 0.00x | 1.04x | €-1.90 Million |
| 2026 | -92.72% | 0.00% | 0.00x | 1.23x | €-6.36 Million |
Industry Comparison
This section compares GRAFT POLYMER UK LS -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $685,731,838
- Average return on equity (ROE) among peers: -86.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GRAFT POLYMER UK LS -001 (J4I) | €6.19 Million | -59.40% | 0.23x | $7.90 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $1.61 Million | -354.52% | 1.11x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $41.39 Million | -67.94% | 2.33x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-338.57 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $183.88 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $888.51 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more